MAOYAN ENT (01896) opened over 4% higher, rising 4.05% to HK$7.19 by the time of writing, with a turnover of HK$1.29 million. The surge follows the stronger-than-expected weekend performance of "Zootopia 2," which has broken multiple box office records in China. According to Lighthouse Pro, the film's cumulative box office in China surpassed RMB 1.9 billion as of November 30. Platforms including MAOYAN ENT have significantly raised their total box office forecast for the movie from RMB 2.4 billion to RMB 4.263 billion. Additionally, over 70 brands in China have launched co-marketing campaigns tied to the film's release. Huayuan Securities noted that imported films' box office performance remains a key focus, as the market continues to be supply-driven. High-quality sequels with strong track records in China are expected to boost demand and drive steady growth in box office revenue. CITIC Securities highlighted that MAOYAN ENT's interim report extensively discussed its IP business strategy for the first time, emphasizing experimental operations to build experience. The firm believes future opportunities lie in scaling up film IP operations systematically, integrating promotion with IP-derived synergies.